psalexa
logo

Japanese Encephalitis (JE) Therapeutics Pipeline Analysis, 2017

Japanese Encephalitis (JE) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: October 2017
Report Code: LS11316
Available Format:
Pages: 60

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Japanese encephalitis (JE) is a viral infection that spreads by mosquito bites, causing brain inflammation and swelling due to bacterial or viral infections in the brain. The sign and symptoms of Japanese encephalitis infections are mild in nature such as fever and headache. The severe form of Japanese encephalitis is characterized by symptoms such as rapid onset of coma, disorientation, high fever, headache, neck stiffness, seizures, spastic paralysis and ultimately death. The confirmatory diagnosis of JEV infection requires a laboratory testing of serum or preferentially, cerebrospinal fluid to detect virus-specific Immunoglobulin M (IgM) antibodies.  Spring Bank Pharmaceuticals, Inc. is in the process of developing SB 9200, which is in the discovery stage of development for the treatment of Japanese encephalitis. Some of the companies developing drugs for the treatment of Japanese encephalitis are Ennaid Therapeutics, LLC, Panacea Biotec Ltd., VABIOTECH and others.

 

JAPANESE ENCEPHALITIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
JAPANESE ENCEPHALITIS THERAPEUTICS
 

Pipeline Analysis

As of October 2017, the Japanese encephalitis therapeutics pipeline comprises of 12 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.

 Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry